ATE366816T1 - Typ ii tgf-beta receptor/immunoglobulin konstante domäne fusionsproteine - Google Patents

Typ ii tgf-beta receptor/immunoglobulin konstante domäne fusionsproteine

Info

Publication number
ATE366816T1
ATE366816T1 AT98918247T AT98918247T ATE366816T1 AT E366816 T1 ATE366816 T1 AT E366816T1 AT 98918247 T AT98918247 T AT 98918247T AT 98918247 T AT98918247 T AT 98918247T AT E366816 T1 ATE366816 T1 AT E366816T1
Authority
AT
Austria
Prior art keywords
fusion proteins
tgf
immunoglobulin constant
type
constant domain
Prior art date
Application number
AT98918247T
Other languages
English (en)
Inventor
Philip Gotwals
Victor Koteliansky
Richard Cate
Michelle Sanicola-Nadel
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE366816T1 publication Critical patent/ATE366816T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
AT98918247T 1997-04-18 1998-04-16 Typ ii tgf-beta receptor/immunoglobulin konstante domäne fusionsproteine ATE366816T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4464197P 1997-04-18 1997-04-18

Publications (1)

Publication Number Publication Date
ATE366816T1 true ATE366816T1 (de) 2007-08-15

Family

ID=21933495

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98918247T ATE366816T1 (de) 1997-04-18 1998-04-16 Typ ii tgf-beta receptor/immunoglobulin konstante domäne fusionsproteine

Country Status (22)

Country Link
US (1) US20050203022A1 (de)
EP (1) EP0975771B1 (de)
JP (2) JP2001515360A (de)
KR (1) KR20010006534A (de)
CN (1) CN1257545A (de)
AT (1) ATE366816T1 (de)
AU (1) AU737106B2 (de)
BR (1) BR9808934A (de)
CA (1) CA2286933A1 (de)
DE (1) DE69838061T2 (de)
DK (1) DK0975771T3 (de)
EA (1) EA199900947A1 (de)
EE (1) EE9900492A (de)
ES (1) ES2289778T3 (de)
IL (1) IL132249A0 (de)
IS (1) IS5217A (de)
NO (1) NO994998L (de)
NZ (1) NZ500284A (de)
PL (1) PL336306A1 (de)
PT (1) PT975771E (de)
TR (1) TR199902878T2 (de)
WO (1) WO1998048024A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6492325B1 (en) 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
EP1087998A1 (de) * 1998-06-16 2001-04-04 Biogen, Inc. Variante tgf-beta rezeptor typ ii fusionsproteine und verfahren
DE1221490T1 (de) 1999-09-17 2003-05-28 Tgt Lab S A De C V Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von unterschiedlichen typen der leber-, nieren- und lungenfibrose und hypertrophischen narben
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
MXPA00011713A (es) * 2000-11-28 2002-05-31 Tgt Lab S A De C V Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
KR100976743B1 (ko) * 2001-05-24 2010-08-19 지모제넥틱스, 인코포레이티드 Ｔａｃｉ-면역글로불린 융합 단백질
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
WO2007050793A2 (en) 2005-10-25 2007-05-03 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
EP1998810A4 (de) 2006-03-13 2009-09-02 Univ Johns Hopkins Erhöhung der endothelialen thromboresistenz
WO2008067025A2 (en) * 2006-09-29 2008-06-05 Evanston Northwestern Healthcare Oncolytic adenoviruses and uses thereof
PL2918288T3 (pl) 2006-10-03 2018-02-28 Genzyme Corporation Zastosowanie antagonistów TGF beta do leczenia niemowląt obarczonych ryzykiem rozwinięcia dysplazji oskrzelowo-płucnej
EP2171062A1 (de) * 2007-06-15 2010-04-07 Genzyme Corporation Fusionsproteine mit zwei tgf-beta-bindungsdomänen des tgf-beta-typ-ii-rezeptors
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
US8592364B2 (en) * 2010-02-11 2013-11-26 Ecole Polytechnique Federale de Lausanne (“EPFL”) CCR7 ligand delivery and co-delivery in immunotherapy
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CA2807942C (en) 2010-08-10 2021-07-27 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
KR20130131414A (ko) 2010-12-27 2013-12-03 엘에스아이피 환도 운에이고우도우가이샤 ｉＰＳ 세포와 그 제조법
CN102175501A (zh) * 2011-01-07 2011-09-07 山东省农业科学院作物研究所 用于显微镜观察的植物样品的前处理方法
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
CN102898508B (zh) * 2011-08-12 2014-04-30 北京大学第一医院 封闭TGF-β受体或IL-10受体的多肽、其药物组合物及其用途
CA2853484C (en) 2011-10-26 2018-08-21 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
ES2917222T3 (es) 2011-12-28 2022-07-07 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
AU2013220079B2 (en) 2012-02-15 2017-10-05 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
CN105658672A (zh) * 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
CA2927898C (en) 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
CN105934249A (zh) * 2013-11-21 2016-09-07 布里格姆及妇女医院股份有限公司 用于治疗肺高压的组合物和方法
AR098827A1 (es) 2013-12-19 2016-06-15 Consejo Nac De Investig Científicas Y Técnicas (Conicet) ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS
MX381141B (es) * 2014-02-10 2025-03-12 Merck Patent Gmbh INHIBICIÓN DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGF ß).
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
CA2946064C (en) 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
WO2016019368A1 (en) 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
WO2016187312A1 (en) 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
WO2017024171A1 (en) * 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
JP7632835B2 (ja) * 2016-05-20 2025-02-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 加齢関連疾患及び症状の遺伝子治療法
JP7421338B2 (ja) * 2016-09-27 2024-01-24 エピセントアールエックス，インコーポレイテッド 免疫調節融合タンパク質
JP7231553B2 (ja) * 2017-03-02 2023-03-01 ナショナル リサーチ カウンシル オブ カナダ Ｔｇｆ－ｂ－受容体外部ドメイン融合分子及びその使用
CN110785431B (zh) * 2017-05-04 2024-05-07 阿塞勒隆制药公司 TGF-β受体II型融合蛋白及其用途
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
AU2018338612A1 (en) 2017-09-27 2020-05-07 Epicentrx, Inc. Immunomodulatory fusion proteins
CN112119157B (zh) 2018-03-06 2025-01-14 宾夕法尼亚大学董事会 前列腺特异性膜抗原car及其使用方法
BR112020017382A2 (pt) 2018-03-09 2021-01-26 Agenus Inc. anticorpos anti-cd73 e métodos de uso dos mesmos
US11168138B2 (en) 2018-03-26 2021-11-09 Altor Bioscience, Llc Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
AU2019265734B2 (en) 2018-05-09 2026-03-19 Anokion Sa Compositions and methods concerning immune tolerance
AU2019301070B2 (en) 2018-07-09 2025-09-11 Precigen, Inc. Fusion constructs and methods of using thereof
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
CN114173806A (zh) * 2019-07-26 2022-03-11 密歇根州立大学董事会 预防或治疗骨骼肌脂肪变性的方法
WO2021041886A1 (en) * 2019-08-29 2021-03-04 Nantbio, Inc. Modified n-810 and methods therefor
US12527839B2 (en) 2019-11-05 2026-01-20 Acceleron Pharma Inc. Treatments for systemic sclerosis
IL299764A (en) 2020-07-10 2023-03-01 Precigen Inc Fusion constructs and methods for using them
CN113968903A (zh) * 2020-07-24 2022-01-25 迈威(上海)生物科技股份有限公司 TGF-β RII突变体及其融合蛋白
AU2023210700A1 (en) 2022-01-28 2024-08-15 35Pharma Inc. Activin receptor type iib variants and uses thereof
WO2023206188A1 (en) * 2022-04-28 2023-11-02 Wenzhou Prarucom Bio-Chemical Technology Co. Method for alleviating pulmonary fibrosis using epidermal growth factor
CN116676344A (zh) * 2023-05-31 2023-09-01 中国人民解放军总医院第八医学中心 稳定表达TGF-βII型受体的工程化巨噬细胞及其在肺纤维化治疗中的应用
EP4653010A1 (de) 2024-05-14 2025-11-26 35Pharma Inc. Activinrezeptor-typ-iib-varianten und verwendungen davon

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4874702A (en) * 1980-09-08 1989-10-17 Biogen, Inc. Vectors and methods for making such vectors and for expressive cloned genes
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
AU669256B2 (en) * 1992-10-29 1996-05-30 Celtrix Pharmaceuticals, Inc. Uses of TGF-beta receptor fragment as a therapeutic agent
ES2114183T5 (es) * 1993-02-09 2006-06-16 Biogen Idec Ma, Inc. Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

Also Published As

Publication number Publication date
EP0975771B1 (de) 2007-07-11
EP0975771A1 (de) 2000-02-02
EA199900947A1 (ru) 2000-04-24
DK0975771T3 (da) 2007-10-22
JP2008106076A (ja) 2008-05-08
NZ500284A (en) 2001-09-28
NO994998L (no) 1999-12-20
NO994998D0 (no) 1999-10-14
BR9808934A (pt) 2000-08-01
PT975771E (pt) 2007-10-01
EE9900492A (et) 2000-06-15
JP2001515360A (ja) 2001-09-18
AU7120898A (en) 1998-11-13
ES2289778T3 (es) 2008-02-01
WO1998048024A1 (en) 1998-10-29
AU737106B2 (en) 2001-08-09
IL132249A0 (en) 2001-03-19
IS5217A (is) 1999-10-15
DE69838061D1 (de) 2007-08-23
PL336306A1 (en) 2000-06-19
DE69838061T2 (de) 2008-03-13
TR199902878T2 (xx) 2000-02-21
CA2286933A1 (en) 1998-10-29
CN1257545A (zh) 2000-06-21
US20050203022A1 (en) 2005-09-15
KR20010006534A (ko) 2001-01-26

Similar Documents

Publication Publication Date Title
ATE366816T1 (de) Typ ii tgf-beta receptor/immunoglobulin konstante domäne fusionsproteine
DE69536078D1 (de) Inhibitoren
CY2005008I1 (el) Αντισωματα αντι - vegf
KR950700779A (ko) 단백질의 정제방법(Protein purification)
DE19882126T1 (de) Hydrierung von Kohlenwasserstoffen
DK0911416T3 (da) Fremgangsmåde til fremstilling af protein
FI964845L (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
EA200100012A1 (ru) Мостиковые инденопирролокарбазолы
TR200101703T2 (tr) Aktif limfotoksin-ß reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.
NO960611D0 (no) Bitumenholdig blanding
PT1027339E (pt) Metodo e reagentes para a n-alquilacao de ureidos
BR9708347A (pt) Compostos de tetrahidorbeta-carbonila
ATE288909T1 (de) Indolderivate verwendbar zur behandlung von u.a. osteoporosis
EP1017716A4 (de) Car-rezeptoren, verwandte moleküle und methoden
DE69811677D1 (de) Verfahren zur präparation von enantiomer-angereicherten, n-derivatisierten laktamen.
DK1208213T3 (da) Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner
DK0829579T3 (da) Farbart bindelag og fremgangsmåde til den fremstilling
DE59813125D1 (de) Srcr domäne-enthaltendes protein
CY1106887T1 (el) Πρωτεϊνες συντηξης τυπου ii tgf-b υποδοχεα/σταθερης περιοχης ανοσοσφαιρινης
NL1002352A1 (nl) Groep bestratingsstenen.
KR970001929U (ko) 도로안내용 반사판
NL1001013A1 (nl) Technoclip.
ES1037297Y (es) Poste para acotacion de areas transitables.
KR970016491U (ko) 스프링 타입용 지그
KR970032623U (ko) 헤드 램프 빔 조정장치

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee